item management s discussion and analysis of financial condition and results of operations except for the historical information contained in this annual report  the matters discussed in management s discussion and analysis of financial condition and results of operations are forward looking statements  the accuracy of which is necessarily subject to risks and uncertainties 
actual results may differ significantly from the discussion of such matters in the forward looking statements 
results of operations the following table sets forth the percentage of total revenues represented by certain items reflected in the company s income statement for the period indicated and the percentage increase or decrease in such items over the prior period 
percentage of total revenues percentage change december  december  january  vs 
vs 
total revenues cost of sales gross profit costs and expenses general and administrative marketing and selling research and development restructuring  impairment and other non recurring charges total costs and expenses operating income loss other expense  net income loss before income taxes income tax provision benefit accounting change elimination of minority interest net income fiscal year compared to fiscal year revenues 
revenues for the year ended december  were million  representing a decrease over the million in revenues for the year ended december  the primary reasons for the decrease in revenues were the reduced us dollar amounts recorded by international subsidiaries due to the strength of the us dollar as compared to foreign currencies most specifically the german mark  decreased sales to the company s joint venture canonstaar  continuing decline in sales of the company s silicone iol s in europe and lower average selling prices on international sales of the company s implantable contact lens due to the change from direct selling to selling through international distributors 
these decreases were offset by increased sales of the sonic wave phacoemulsification system which was introduced in the third quarter  increased revenue from the sales of the collamer single piece iol approved for sale in april  increased revenues from sales of toric iol  and increased revenues from a full year of sales of custom surgical packs to our us customers which began in mid year other revenue in increased over by  the company is expanding its market focus beyond the cataract market to also include the refractive and glaucoma markets 
the company anticipates its growth in the refractive and glaucoma product markets will increase as the company s refractive lenses icl and toric iol and its glaucoma aquaflow product lines continue to gain market acceptance 
the company believes its sales of products used for the treatment of cataracts will grow with its increased international presence  its us approval of new products such as its collamer iol and the introduction of the sonic wave phacoemulsification system 
cost of sales 
cost of sales increased to of revenue for the year ended december  from of revenue for the year ended december  the primary reason for this increase relates to an inventory write off of million  recorded during the second quarter of  of various items that no longer fit the company s future direction 
additionally  despite higher average selling prices for iols  higher average unit cost caused the cost of sales as a percentage of revenue exclusive of the above mentioned write off to increase slightly to 
the increase in average selling price was due to the change in product mix to the company s premium priced iol s toric and collamer 
the higher average cost of iol s was due principally to the changes in product mix to the collamer iol and to a lesser extent increased unit cost due to lower manufacturing activity levels causing the units produced to carry a higher per unit cost from absorption of fixed expenses 
additionally the full year of sales of custom surgical packs in the us  have a higher cost of sales as a percentage of sales when compared to the other products the company offers 
the company expects iol unit growth in to be modest and combined with a plan of reducing overall inventory the company expects the cost of units produced in to increase 
the company will not be able to reduce the costs of sales to levels attained in and prior years until sales of its refractive lenses and its aquaflow glaucoma device make up a larger percent of the company s overall revenues 
general and administrative 
general and administrative expense for the year ended december  were million or of revenue as compared to million or of revenue for the year ended december  this increase in dollars is primarily attributable to increases in expenditures for professional service fees  expenses recorded in the second quarter at the time of the company s restructuring plan and  increased expenses year over year from subsidiaries acquired or created in late the increase as a percent of revenues was due to the expenses increasing at a rate greater than the current growth rate of revenues 
marketing and selling 
marketing and selling expenses for the year ended december  were million or of revenue as compared to million or of revenue for the year ended december  the primary reasons for this increase are the compensation and travel costs related to direct sales management for iol sales and the company s sonic wave phacoemulsification system which were established during late and  increased commissions generated by the graduated commission schedule which has higher percentage rates as iol sales price increases  average selling prices increase over due to the change in iol mix to the company s proprietary iol s 
additionally the company has continued to increase the expenses for product management to prepare for broader entry into the refractive and glaucoma markets 
these increases were offset in part due to the reduced us dollar amounts recorded by international subsidiaries due to the strength of the us dollar as compared to foreign currencies most specifically the german mark 
research and development 
research and development expenses for the year ended december  were million or of revenue as compared to million or of revenue for the year ended december  research and development expense decreased slightly over the prior year due reduction in r d staffing offset by increased spending related to the monitoring of clinical trials for the icl for the correction of myopia  icl for the correction of hyperopia and the aquaflow glaucoma device 
additionally expenses increased related to the development and improvement of company s sonic wave phacoemulsification system 
the company expects research and development expense to be in the range of million to million 
restructuring  impairment and other non recurring charges on june   the company announced the details of its plan of restructuring 
in conjunction with the implementation of the plan  the company recorded a pretax charge to earnings of million in the second quarter of fiscal the changes include approximately million for restructuring of certain subsidiaries  approximately million to write off patents that were considered questionable in providing future value to the company  approximately l 
million of costs incurred by the company relating to activities that were abandoned  approximately million relating to severance and other employee separation costs  approximately million relating to the disposition of investment and assets related to the company s abandoned entry into the lasik market  and approximately million relating to the closure of a foreign subsidiary 
employees were laid off  terminated or resigned as part of the company s restructuring plan 
other expense or income  net 
other expense for the year ended december  was a net of approximately million or of revenues as compared to approximately million or of revenues for the prior year 
the primary reasons for this increase were million charge relating to the write off of its japanese joint venture and a charge to related to a note receivable from a former officer which is currently under collateralized 
the company s disputes with its japanese joint venture partners are currently in arbitration 
income tax provision 
income tax benefit was million for the year ended december  as compared to a provision of 
million for the year ended december  the reasons for the change relate to the dramatic reduction in income before income taxes which was due primarily to the charges taken in the second quarter which totaled million before income taxes 
during  the company recorded a deferred tax asset that resulted from the losses recorded for the year 
the company has been profitable in the past and with the introduction of new products expects to return to profitability in the future 
the company would have been profitable in the current year with the exclusion of charges relating to the restructuring plan and the reserve for notes receivable 
the company expects to have adequate future earnings to take advantage of the amounts recorded 
fiscal year compared to fiscal year revenues 
revenues for the year ended december  were million  representing a increase over the million in revenues for the year ended january  the primary reasons for the increase in revenues were increased iol market share in the united states which had been lost in due to a new product introduction by a competitor  increased revenue from the sales of the toric iol  increased revenue from sales of the company s icls and revenue from new activities in the united states 
incremental revenues from the increase in united states iol market share  exclusive of increases related to sales of the company s toric iol  amounted to approximately million  incremental revenue from the company s toric iol and the company s icls was approximately million and million respectively 
during the company formed a wholly owned subsidiary that operates refractive laser centers and began selling custom surgical packs to its us customers 
revenue from these new activities accounted for approximately million 
these increases were offset partially due to a decline in other revenue 
cost of sales 
cost of sales increased to of revenue for the year ended december  from of revenue for the year ended january  the primary reasons for this increase relates to lower average selling prices for iols  higher cost to manufacture during the second half of and early and in a shift in product mix to the three piece elastimide lens which  by its design  is more costly to manufacture 
the decline in average selling price was due in part to the addition of a very large customer and the bulk sale of iols during the fourth quarter at lower than average pricing 
the reduced sales in resulted in lowered production activity in the second half of and early therefore  the units produced in those time periods reflected a higher per unit cost from absorption of fixed expenses 
additionally new activities of  laser centers and custom surgical packs  have a higher cost of sales as a percentage of sales when compared to the other products the company offers 
general and administrative 
general and administrative expense for the year ended december  was million  or of revenues  as compared to million  or of revenues for the prior fiscal year 
this increase in dollars is primarily attributable to the company starting to build the administrative infrastructure required to support the expected growth as its new products enter the marketplace 
additionally  there were increases in professional service fees  the costs of administration of the new laser center subsidiary  and travel and other expenses resulting from managing the sales subsidiaries 
the increase as a percent of revenues was due to the expenses increasing at a rate greater than the current growth rate of revenues 
marketing and selling 
marketing and selling expense for the year ended december  was million or of revenues  as compared to million or of revenues for the prior fiscal year 
the primary reasons for this increase are the marketing costs related to the product launch of the company s toric iol in and preparation for the product launch of the collamer iol in early additionally the company has continued to increase the expenses for product management to prepare for broader entry into the refractive and glaucoma markets 
research and development 
research and development expense for the year ended december  was million  or of revenues as compared to million or of revenues for the year ended january  research and development expense increased over the prior year due to increased spending related to monitoring of the clinical trials for the icl for the correction of myopia  icl for the correction of hyperopia and the aquaflow glaucoma device 
additionally expenses increased related to the completion of the patient enrollment and implants for the clinical trial for the icl for the correction of myopia and increased expenditures for developing new injection technologies for iols and icls 
other expense or income  net 
other expense for the year ended december  was a net of approximately 
million or of revenues as compared to approximately 
million or of revenues for the prior year 
the primary cause for the decrease in other expense was due to increased earnings from the company s joint venture with canon staar 
income tax provision 
income tax provision decreased to 
million or of revenues for the year ended december  compared to million or of revenues for the prior fiscal year 
the reasons for the reduction stem from the company s lower pretax earnings and the receipt of more than of its revenues from international sources  where tax rates are more favorable 
liquidity and capital resources the company has funded its activities over the past several years principally from cash flow generated from operations  credit facilities provided by institutional domestic and foreign lenders  private placement of common stock and the exercise of stock options and warrants 
on june   the company announced the details of its plan of restructuring 
in conjunction with the implementation of the plan  the company recorded a pretax charge to earnings of million in the second quarter of fiscal the charges include approximately million for the restructuring of certain subsidiaries  approximately million to write off patents that were determined to have no value to the company  approximately million of costs incurred by the company relating to activities that were abandoned  approximately million relating to severance and other employee separation costs  approximately million relating to the disposition of investment and assets related to the company s abandoned entry into the lasik market  and approximately million relating to the closure of a foreign subsidiary 
of the total restructuring charge  million was accrued for future cash expenditures 
at december   approximately million of accrued expenses remained 
in october  the company completed a private placement with institutional investors of million shares of the company s common stock for net proceeds of million 
the company had a loan agreement with a domestic lender which carried an interest rate not to exceed the prime rate less on any outstanding principal amount 
the loan agreement granted the lender a security interest in the company s accounts receivable  inventories  property  plant and equipment  and other general intangibles 
the loan agreement also required that the company maintain and satisfy certain financial tests and limited the amount of indebtedness the company could incur collectively the restrictive covenants 
the company was current in its payment of principal and interest to the lender as provided for under the loan agreement 
however  the company was not in compliance with certain of the restrictive covenants during the first quarter  and to a larger extent the second quarter of  which is attributable to the restructuring plan 
the company obtained forbearance letters from the lender who agreed to forbear from exercising its rights and remedies under the loan agreement 
in an agreement with the lender  the company paid off all of its term debt and a portion of its line of credit with funds obtained through the private placement of shares of the company s common stock and renegotiated its line of credit 
the new agreement provides a line of credit not to exceed million at a rate of interest equal to the prime rate at december  and grants the lender a security interest in the company s accounts receivable  inventories  property  plant and equipment  and other general intangibles 
the agreement has certain financial ratios and other restrictive covenants including the maintaining of minimum cash balances 
the note as amended is due on july  the company was not in compliance with the net income covenant at december  but obtained a waiver from the lender who agreed to waive its rights and remedies under the loan agreement 
borrowings outstanding as of december  were  the company is in the process of seeking alternative financing to pay down or payoff the line of credit  however there is no assurance the company will be successful in obtaining the necessary financing or obtaining financing on favorable terms 
during  the company renegotiated its revolving credit facility with a foreign lender 
the new agreement provides for borrowings under a revolving credit facility and also provides for fixed term loans 
maximum allowable borrowings under the revolving credit facility are   swiss francs at the exchange rate at december   at an interest rate of per annum and a credit commission of 
payable quarterly on the average debit balance 
the loan does not have a termination date and is secured by a general assignment of claims 
borrowings outstanding under the credit facility as of december  were   swiss francs 
the fixed term loan provides for borrowings of up to   swiss francs 
minimum advances of chf  may be made for periods of to years 
payments in the amount of chf  are due semi annually beginning june  the base interest rate used follows euromarket conditions for loans of the corresponding term and currency 
there were no borrowings outstanding under the term loan as of december  the company has a revolving overdraft facility with another foreign lender which provides for borrowings of up to approximately  million deutsch marks at the exchange rate at december   at an interest rate of 
the loan is renewed annually with a due date of may  and is secured by an assignment of accounts receivable and inventory 
borrowings outstanding as of december  and december  were  dm  and  dm  respectively 
as of december   the company had net working capital of approximately million as compared to million and million as of december  and january   respectively 
the decrease in working capital as of december  is primarily due to the reclassification of long term debt to notes payable as a result of the company not fulfilling the bank s financial covenants 
the increase in working capital from january  to december  was due to increases in inventories of million  prepaid and deposits of million  other current assets of million  and a decrease in current deferred income tax of million  offset by a decrease in cash of million and increases in accounts payable or million and other current liabilities of million 
cash and cash equivalents were million at december   an increase of million from december  the increased cash is primarily the result of funds received from a private placement of the company s common stock after having paid off the company s long term debt and a portion of its line of credit 
the decline in the company s cash position as of december  was due to increased investment in property and equipment in preparation for the launch of the collamer iol 
cash flows used in operating activities for the year ended december  were approximately million  compared to and when operating activities generated approximately million and million  respectively 
the increase related to changes in working capital is due primarily to increases in inventory  due to the launch of the collamer iol in the united states  of approximately million  and accounts receivable of approximately million 
these increases exclude the impact of restructuring write offs 
additionally  the company reduced its accounts payable during by approximately million 
working capital changes had a far lesser impact on cash in due to the fact that increases in inventories and prepaids  deposits  and other current assets were offset by corresponding increases in accounts payable and other current liabilities 
cash used in investing activities for the year ended december  were million compared to december  and january  when the company used and in investing activities 
the change relates to an overall decrease in investments and in particular to decreased patent costs of approximately million  decreased purchases of property and equipment of approximately million and a decrease in other assets and acquisitions of approximately million 
cash used in investing activities for the year ended december  increased over the previous year due to increased purchases of property and equipment and patents offset by a decrease in acquisitions 
cash flows from financing activities for the year ended december  were approximately million compared to december  and january  when they were approximately million and million  respectively 
the increase is due to proceeds of approximately million from a private placement of the company s common stock offset by payments on notes payable and long term debt 
the increase in cash from financing activities for the year ended december  was attributable to an increase in proceeds from the issuance of common stock of approximately million 
the company s capital expenditures for the fiscal years ended december  and december  were approximately million and million  respectively 
the expenditures were used to upgrade existing production equipment  to set up new production facilities for new products  and to reduce current manufacturing costs 
the company s planned capital expenditures for are approximately million  to be used for the continuous improvement of manufacturing processes 
capitalized additions for patents and licenses for the year ended december  and december  were approximately 
million and million  respectively 
the company capitalizes the costs of acquiring patents and licenses as well as the legal costs of defending its rights to the patents 
the company expects to spend approximately 
million in for patents and licenses 
management believes that cash flow from operations and available credit facilities  together with its current cash balances  will provide adequate economic resources to fund existing operations 
foreign exchange management does not believe that the fluctuation in the value of the dollar in relation to the currencies of its suppliers or customers in the last three fiscal years has adversely affected the company s ability to purchase or sell products at agreed upon prices 
no assurance can be given  however  that adverse currency exchange rate fluctuations will not occur in the future  which would affect the company s operating results 
see uncertainties and risk factors risks associated with international transactions below 
inflation management believes inflation has not had a significant impact on the company s operations during the past three years 
new accounting pronouncements in june  the financial accounting standards board fasb issued sfas no 
 accounting for derivative instruments and hedging activities  which the company adopted in this statement establishes accounting and reporting standards requiring every derivative instrument  including certain derivative instruments embedded in other contracts  be recorded in the balance sheet as either an asset or liability measured at its fair value 
the statement also requires changes in the derivative s fair value be recognized in earnings unless specific hedge accounting criteria are met 
the company s adoption of sfas did not have a material impact on the consolidated financial statements 
in december  the securities and exchange commission sec released staff accounting bulletin sab no 
 revenue recognition in financial statements  which provides guidance on the recognition  presentation and disclosure of revenue in the financial statements filed with the sec 
subsequently  the sec released sab b  which delayed the implementation date of sab for registrants with fiscal years that begin between december  and march  the company was required to be in conformity with the provisions of sab  as amended by sab b  no later than october  the company believes the adoption of sab  as amended by sab b  has not had a material effect on the financial position  results of operations or cash flows of the company for the year ended december  in march  the fasb issued interpretation no 
 accounting for certain transactions involving stock compensation  the interpretation of apb opinion no 
fin 
the interpretation is intended to clarify certain problems that have arisen in practice since the issuance of apb no 
 accounting for stock issued to employees 
the effective date of the interpretation was july  the provisions of the interpretation apply prospectively  but they will also cover certain events occurring after december  and after january  the company believes the adoption of fin has not had a material affect on the current and historical consolidated financial statements  but may affect future accounting regarding stock option transactions due to the repricing discussed in note item a 
quantitative and qualitative disclosures about market risk all sales by the company are denominated in us dollars or the currency of the country of origin and  accordingly  the company does not enter into hedging transactions with regard to any foreign currencies 
currency fluctuations can  however  increase the price of the company s products to its foreign customers which can adversely impact the level of the company s export sales from time to time 
the majority of the company s cash equivalents are bank accounts  and the company does not believe it has significant market risk exposure with regard to its investments 

